Subscribe to our Newsletters !!
The connection between genes and traits is one of
Our customers depend on the high performance and r
Few names in the medical history have had a profou
Alembic Pharmaceuticals Limited appoints Mr. Manis
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
AstraZeneca, the British drugmaker working on one of the world’s leading COVID-19 vaccine candidates, conquer third-quarter sales estimates on Thursday and reiterated it expects data from late-stage trials of the vaccine later this year.
The business has taken on the development of Oxford University’s potential COVID-19 vaccine, scoring billions in funding and signing multiple prices to provide over three billion doses to nations around the world.
Data in October showed the vaccine, called AZD1222 or ChAdOx1 nCoV-19, produces an immune response in both old and young adults. AstraZeneca is expected to publish eagerly awaited late-stage clinical trial data in the coming weeks.
Expectations are that Britain could start rolling out a successful vaccine in late December or early 2021.
While AstraZeneca marches on with the vaccine, demand for its diverse portfolio of drugs remained strong despite disruptions to health systems because of the pandemic.
Product sales, which exclude payments from collaborations, rose 7% to $6.52 billion for the three months ended Sept. 30 on a constant-currency basis, before a company-compiled consensus of $6.50 billion.
However, the company reported core earnings of 94 cents per share, lower than analysts’ expectations of 98 cents.
AstraZeneca said it still expects total revenue to increase by a high single-digit to a low double-digit percentage and core earnings per share to increase by a mid- to high-teens percentage.
